UK NEXT-DAY DELIVERYMon–Fri before 3pm 3pm UK cutoff
Oct 12, 2026 Peptide Science

Melanotan 2 (MT2): Research Overview and UK Status

Illustrative PeptidesNextDay Melanotan II 10mg research vial on a white background.

Disclaimer: All products and information referenced are supplied strictly for laboratory and research purposes only and are not medical advice.

Melanotan 2 (MT2) is a synthetic cyclic peptide modelled on alpha-melanocyte-stimulating hormone (α-MSH), the hormone that signals skin cells to produce melanin. It activates several melanocortin receptors, which is why it appears in research on pigmentation, appetite and central melanocortin signalling. This overview covers its structure, what the research has looked at, how it compares to Melanotan 1 and PT-141, and where it stands legally in the UK.

What is Melanotan 2?

Melanotan 2 was developed at the University of Arizona in the late 1980s and 1990s as part of a project looking for a way to stimulate skin pigmentation and reduce skin cancer risk. Researchers shortened and cyclised α-MSH to make it more potent and longer-lasting than the natural hormone.

Key facts

  • Structure: cyclic heptapeptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
  • Approx. molecular weight: 1,024 Da
  • Also called: MT2, MT-II, Melanotan II
  • Receptor activity: non-selective agonist at MC1R, MC3R, MC4R and MC5R

How Melanotan 2 works: the melanocortin system

MT2’s effects in research all trace back to which melanocortin receptor it activates. Because it is non-selective, it hits several at once.

  • MC1R: found on melanocytes; drives eumelanin (dark pigment) production.
  • MC3R and MC4R: found in the brain; involved in energy balance, appetite and sexual function.
  • MC5R: involved in exocrine gland function.

This lack of selectivity is the main reason MT2 was never developed into a medicine: researchers moved to compounds that target one receptor more cleanly.

What Melanotan 2 research has reported

Pigmentation

MT2 was first developed at the University of Arizona to study melanocortin-driven pigmentation. That early work was small-scale pilot research, not licensing trials.

MC4R signalling

Effects on central MC4R signalling seen in that early work led directly to the development of PT-141 (bremelanotide), a more MC4R-focused derivative.

Appetite and energy balance

Through MC4R, MT2 has been used in animal studies of food intake and body weight.

Research cautions

Because MT2 stimulates melanocytes, dermatology researchers and cancer charities have raised concerns about its effects on melanocytic lesions.

Melanotan 1 vs Melanotan 2 vs PT-141

Melanotan 1Melanotan 2PT-141
StructureLinear, 13 amino acidsCyclic, 7 amino acidsCyclic, 7 amino acids (MT2 derivative)
Receptor focusMainly MC1RMC1R, MC3R, MC4R, MC5RMainly MC4R and MC3R
Licensed?Yes, as afamelanotide (Scenesse) for a rare light-sensitivity disorderNoUS only, as Vyleesi

UK regulatory status

In summary:

  • Not a licensed medicine: Melanotan 2 has no marketing authorisation in the UK or anywhere else.
  • MHRA position: the MHRA has warned against the sale of Melanotan products, as reported by Cancer Research UK.
  • Research use only: PeptidesNextDay supplies MT2 solely for laboratory research.

Our guide to whether peptides are legal in the UK covers the wider rules.

Handling MT2 research vials

  • Before reconstitution: store lyophilised powder at −20°C, protected from light.
  • After reconstitution: refrigerate and avoid freeze–thaw cycles.
  • Diluent: see our bacteriostatic vs sterile water guide.

Melanotan 2 FAQs

Is MT2 the same as Melanotan 2?

Yes. MT2, MT-II and Melanotan II are all names for the same synthetic cyclic peptide.

What is the difference between Melanotan 1 and Melanotan 2?

Melanotan 1 (afamelanotide) is a linear peptide that is more selective for the MC1 receptor and is a licensed medicine for one rare condition. Melanotan 2 is a shorter cyclic peptide that acts on several melanocortin receptors and is not licensed anywhere.

Is Melanotan 2 legal in the UK?

Melanotan 2 is not a licensed medicine in the UK. The MHRA has warned against its sale as an unlicensed product. It can be supplied strictly for laboratory research.

How is PT-141 related to Melanotan 2?

PT-141 (bremelanotide) is a close derivative of Melanotan 2, developed by Palatin Technologies, with a carboxylic acid in place of the terminal amide group of MT2.

Summary

Melanotan 2 is a potent, non-selective melanocortin agonist with a research history in pigmentation, appetite and MC4R signalling. It is not a licensed medicine. For laboratory work, PeptidesNextDay stocks Melanotan II 10mg at ≥98% purity, with batch documentation available on request.

Important Product Notice

PeptidesNextDay supplies specialist peptide products with clear product information and practical handling notes where available. Products are not approved for human or veterinary administration and must not be used for therapeutic, diagnostic, clinical, or self-administration purposes.

Not a Medicine: Our peptides have not been evaluated by the MHRA, FDA, or any equivalent regulatory authority for safety or efficacy in humans or animals.

Buyer Responsibility: By placing an order with PeptidesNextDay, you confirm that products will be handled only where lawful and appropriate, in accordance with applicable local laws and regulations, and that you accept full responsibility for their storage, handling, and use.

Non-Returnable Products: Due to the specialist nature of peptide compounds and the quality-control requirements of our supply chain, we are unable to accept returns once an order has been dispatched.

Proceeding with a purchase on this site constitutes your acceptance of these conditions. If you have any questions prior to ordering, our team is available via the contact page.